Genitourinary medical oncologist @UTMDAnderson. Likes: clinical trials, cycling, Miami hurricanes, Jeopardy!
Houston, TX
Joined July 2018
- Tweets384
- Following510
- Followers464
- Likes1.8K
Mike Glover retweeted
🚨📝checkout our newest #bladdercancer paper. Skin tox (🟡 on swimmers plot) common and early in EVP and linked to better outcomes in la/mUC. We also provide landmark and Simon-Makuch analyses.
🙏 stat editors @JAMANetworkOpen
🌟🥇@DrZachariahT
Co-mentor @DocMattCampbell – at Madrid, Spain
In advanced #UrothelialCarcinoma, treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer overall survival. ja.ma/4k88Qvf
ALT A horizontal bar chart showing time since EVP indication in months on the x-axis, accompanied by categorical side columns for skin toxic effects, best response, and vital status. Below is a density plot peaking sharply near zero.
Mike Glover retweeted
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!
Exciting day in GCT as @DrDarrenFeldman presents data on ixo-V, a CLDN6 ADC. High response rate in refractory setting. More patients will be needed to evaluate durability and responses across histologies
Mike Glover retweeted
(1/4) Here's our clinical lab’s latest work led by @MitchellBoshkos, PGY-3, evaluating how cardiometabolic factors influence response to pre-operative ADT +/- ARPI in localized HRPCa in @pcan_journal
tinyurl.com/3u8r4vf9
Mike Glover retweeted
The pre-operative model to learn how immunotherapies can improve outcomes in prostate cancer. Outstanding talk by @sumit_subudhi @UTMDAnderson
Look out for Zac this application season and beyond! Super hard working, smart and a great team player. Program will be lucky to have him
Hello everyone, I’m Zachariah, a medical graduate from @OffCMCVellore and a postdoctoral fellow at @UTMDAnderson. I’m excited to be applying for the #InternalMedicine Match this year. Grateful to my mentors, @DocMattCampbell and @OAlhalabiMD, and to everyone else who has supported and guided me along the way.
AAMC ID: 17038186
Mike Glover retweeted
I wonder how you would treat a patient after nephro-uretectomy for a high grade, T3N0M0 upper tract urothelial cancer. The tumor is PD-L1+ve and ctDNA-ve. The pateint is not eligible for cisplatin. @DrChoueiri @montypal @PGrivasMDPhD @OncoAlert @Annals_Oncology
22%Surveillance
22%Gem/carbo
31%Nivolumab
24%EV Pembro
565 votes • Final results Mike Glover retweeted
Your patient has had nephrectomy for high-risk clear cell RCC. The next decision: Surveillance, Pembrolizumab, or Pembrolizumab + belzutifan. Is adjuvant justified when surgery may already have been curative? Our new commentary explores this dilemma. 🧵bit.ly/4jkism6
Great work by Zac. ctDNA has potential to detect clinically meaningful changes in disease that has thus far proven to be tricky with other biomarkers (including somatic malignancy and possibly teratoma)
sciencedirect.com/science/ar…
Happy to share a brief report on our experience @UTMDAnderson using circulating tumor DNA(ctDNA) to monitor patients with marker negative germ cell tumors(GCT). Huge thanks to @DocMattCampbell @glovedoc @andrewjohnsmd @OAlhalabiMD for guidance and support.
Mike Glover retweeted
Much appreciated🙏Indeed a broader lesson about rare cancers is that the tools needed to find this dependency (IHC, EGFR mAbs etc.) have existed for decades. What was missing was aggregated samples, purpose-built models, and a mechanism to clinically act on the finding quickly.
Mike Glover retweeted
Happy to share a recently published investigation from @UTMDAnderson on the spectrum of somatic-type malignancies, origin sites and emergence patterns.
Huge thanks to @DocMattCampbell @OAlhalabiMD @andrewjohnsmd @glovedoc for unparalleled mentorship.
academic.oup.com/oncolo/arti…
Congrats to Torstein! Really taking my recommendation for post TC exercise to the next level 😊 @TCSociety @TestesCancer
Mike Glover retweeted
🚀 Now enrolling @UTMDAnderson: STaRMC trial testing sacituzumab tirumotecan in SMARCB1-deficient #RenanMedullaryCarcinoma
👉 clinicaltrials.gov/study/NCT… RMC outcomes have improved but we still lose too many. A key step to #EndRMC. #MsaouelLab #RareCancers #kidneycancer @KidneyCancer
Rare tumors like pheo/para benefit from expert opinion. @OpenMedicineHQ is diffusing this knowledge via free, available algorithms. Check ours out! @PheoPara @NANETS1 @DocMattCampbell
Systemic Therapy Selection for Metastatic Pheochromocytoma and Paraganglioma from @glovedoc: myopenmedicine.com/algorithm…
Mike Glover retweeted
Panitumumab improves survival for patients with RMC, a rare and aggressive variant renal cancer. @PavlosMsaouel is advancing tx for RMC, inspiring! #ASCO26
Mike Glover retweeted
@emanuele_crupi presenting #ASCO26 the phase 2 study results of the GemFLP regimen in urinary tract adenocarcinoma. @ASCO @DocMattCampbell @PGrivasMDPhD @neerajaiims @glovedoc @SGoswamiMDPhD @mjmoussa_ @OncHahn @OAlhalabiMD
Our outstanding post-doc @DrZachariahT presenting data on mediastinal GCT with somatic malignancy. A rare but difficult to treat entity, significantly enriched for sarcoma and p53 mut.
IM program directors be on the look out, he is a ⭐️!
Mike Glover retweeted
If your employer-sponsored insurance copay for a generic is over $15, then 80% of the time, you are overpaying.
In @AnnalsofIM, we analyzed nationwide data on employer plans vs @mcuban’s @costplusdrugs.
Here is a breakdown on who stands to save most. 🧵
NEW: Many patients could pay less for generic drugs by purchasing directly from the Mark Cuban Cost Plus Drug Company @costplusdrugs instead of using employer-sponsored insurance. The findings suggest that patients should consider direct-to-consumer pharmacies for higher out-of-pocket cost #prescriptions. bit.ly/4uZ93Da
Mike Glover retweeted
Honored to present results from the phase II GemFLP trial conducted at The University of Texas MD Anderson Cancer Center in advanced urachal and non-urachal urinary tract adenocarcinoma.
Rapid Oral Session — Hall D2
Monday, June 1 | 8:00 AM #ASCO26
@mjmoussa_ @DocMattCampbell
Mike Glover retweeted
Ab#4520 @ASCO #ASCO26 by @PavlosMsaouel👉 bit.ly/4nHgVqx👉Remarkable clinical activity of EGFR blockade (panitumumab) in SMARCB1-deficient renal medullary mRCC #kidneycancer👉Median PFS 5.8 mo & median OS 9.5 mo👇@NikiZacharias @BradMcG04 @OncoAlert @urotoday @kidneycan
